Can KRAS G12C mutations be treated with sotoraxib (AMG510)?

KRAS gene mutations are extremely common in lung adenocarcinoma, especially the KRAS G12C mutation, which occurs in approximately 13% of such cases. Sotoracib (AMG510) is an irreversible small molecule inhibitor specifically designed to target this mutation. In in-depth studies, sotorasiib showed strong regression effects on tumors harboring the KRAS G12C mutation, and its efficacy was further confirmed in clinical trials in patients with non-small cell lung cancer.

The U.S. Food and Drug Administration (FDA) has officially approved sotorasiib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C mutations who have undergone at least one systemic therapy. The unique mechanism of sotorasibu is that it can tightly bind to the inactive GDP-binding form of KRAS G12C, thereby effectively locking this mutant protein in a dormant state and blocking the transmission of its oncogenic signals.

In the Phase 2 clinical trial namedCodeBreaK 100, sotoraxib demonstrated significant clinical effects in the treatment of previously treated patients with KRAS G12C mutated non-small cell lung cancer. After a long period of follow-up observation, the 1-year survival rate of patients treated with sotoraxib reached 50.8%, the 2-year survival rate was 32.5%, and the median overall survival period was extended to 12.5 months.

Therefore, sotorasiib was not only approved by the FDA as an effective treatment for KRAS G12C mutated non-small cell lung cancer, but also proved its great potential as a first-line treatment in actual treatment. Many patients can still maintain a complete therapeutic response after more than 6 months of treatment, and no obvious toxic reactions occurred during the treatment, showing good tolerance.